Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have confirmed HR+, HER2+ early invasive breast cancer without evidence of disease recurrence or distant metastases~* Have undergone definitive surgery of the primary breast tumor(s)~* Have tumor tissue from breast (preferred) or lymph node~* Have received a minimum of four cycles of chemotherapy in either the neoadjuvant or adjuvant setting per standard of care~* Have completed approximately nine to 20 months of standard HER2-targeted therapy (neoadjuvant/adjuvant combined duration)~* Have received one of the following eligible HER2-targeted adjuvant regimens AND be randomized within 12 weeks of completing the regimen:~  * For participants treated with neoadjuvant therapy and HER2-targeted therapy: A minimum of 4 cycles of T-DM1 in the adjuvant setting. NOTE: Participants may have received up to approximately 6 cycles of adjuvant trastuzumab prior to initiation of T-DM1. Additionally, participants may have switched to trastuzumab-based therapy (monotherapy or in combination with other HER2-targeted therapies) after 4 cycles of T-DM1~ * For participants who had definitive surgery prior to systemic therapy, a minimum of 4 cycles of adjuvant pertuzumab with trastuzumab.~* Have high risk disease, defined by one of the following criteria:~  * Those who received neoadjuvant chemotherapy along with HER2-targeted treatment must have:~    * residual disease in at least one axillary lymph node, or~   * a residual tumor ≥ 5 cm, or~   * a residual tumor of any size that has direct extension to the chest wall and/or skin (ulceration or skin nodules).~ * Those who had definitive surgery prior to systemic therapy and completed adjuvant chemotherapy along with HER2-targeted therapies (trastuzumab and pertuzumab) must have~    * tumor involvement in ≥4 ipsilateral axillary lymph nodes, or~   * tumor involvement in 1 to 3 ipsilateral axillary lymph node(s) and histological Grade 3, or~   * primary invasive tumor size of ≥ 5 cm on pathological evaluation.~Exclusion Criteria:~* Have breast cancer with any of the following features:~  * Disease recurrence or distant metastatic disease (including contralateral axillary lymph nodes)~ * Pathological complete response from any prior early breast cancer treatments. Participants are required to have residual primary tumor and/or lymph node disease at the time of definitive surgery as indicated in inclusion criteria.~ * Inflammatory breast cancer~* Have other medical conditions including:~  * Previous breast cancer (Exceptions: Ipsilateral ductal carcinoma in situ \[DCIS\] treated by locoregional therapy alone ≥5 years ago; contralateral DCIS treated by locoregional therapy at any time)~ * Other cancer being treated and/or not in complete remission within the last 5 years (Exceptions: Appropriately treated non-melanomatous skin cancer or carcinoma in situ of cervix, bladder, or colon)~ * Females who are pregnant or lactating~ * History of venous thromboembolism~ * Other serious medical conditions~* Have previously received treatment with:~  * Any cyclin-dependent kinase (CDK)4 and CDK6 inhibitor~ * Prior adjuvant treatment with immunotherapy, tucatinib, neratinib, any investigational HER2 directed therapy, or T-DXd (DS8201) for treatment of breast cancer~ * Endocrine therapy (ET) (i.e., tamoxifen, raloxifene or aromatase inhibitor) for breast cancer prevention (without diagnosis of breast cancer)~ * Additional chemotherapy, anti-cancer ET, or HER2-targeted therapy beyond standard of care at study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib Plus (+) Endocrine Therapy (ET) (Type: EXPERIMENTAL): Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
- Placebo + ET (Type: ACTIVE_COMPARATOR): Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues